Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease

Abstract Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque burden reduction did not result in clinical bene...

Full description

Bibliographic Details
Main Authors: Jennifer A. Zimmer, Sergey Shcherbinin, Michael D. Devous Sr., Sonja M. Bragg, Katherine J. Selzler, Alette M. Wessels, Craig Shering, Jamie Mullen, John Landry, Scott W. Andersen, AnnCatherine M. Downing, Adam S. Fleisher, Diana Otero Svaldi, John R. Sims
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
amyloid
beta‐site amyloid precursor protein‐cleaving enzyme BACE inhibitor
cerebral metabolism
cerebral perfusion
florbetapir
Online Access:https://doi.org/10.1002/trc2.12123

Internet

https://doi.org/10.1002/trc2.12123

Similar Items